Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
06 2022
Historique:
received: 07 02 2022
accepted: 05 03 2022
entrez: 6 6 2022
pubmed: 7 6 2022
medline: 9 6 2022
Statut: ppublish

Résumé

Deliberative processes for health technology assessment (HTA) are intended to facilitate participatory decision making, using discussion and open dialogue between stakeholders. Increasing attention is being given to deliberative processes, but guidance is lacking for those who wish to design or use them. Health Technology Assessment International (HTAi) and ISPOR-The Professional Society for Health Economics and Outcomes Research initiated a joint Task Force to address this gap. The joint Task Force consisted of 15 members with different backgrounds, perspectives, and expertise relevant to the field. It developed guidance and a checklist for deliberative processes for HTA. The guidance builds upon the few, existing initiatives in the field, as well as input from the HTA community following an established consultation plan. In addition, the guidance was subject to 2 rounds of peer review. A deliberative process for HTA consists of procedures, activities, and events that support the informed and critical examination of an issue and the weighing of arguments and evidence to guide a subsequent decision. Guidance and an accompanying checklist are provided for (i) developing the governance and structure of an HTA program and (ii) informing how the various stages of an HTA process might be managed using deliberation. The guidance and the checklist contain a series of questions, grouped by 6 phases of a model deliberative process. They are offered as practical tools for those wishing to establish or improve deliberative processes for HTA that are fit for local contexts. The tools can also be used for independent scrutiny of deliberative processes.

Identifiants

pubmed: 35667778
pii: S1098-3015(22)00160-7
doi: 10.1016/j.jval.2022.03.018
pmc: PMC7613534
mid: EMS153581
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

869-886

Subventions

Organisme : Wellcome Trust
ID : 203077
Pays : United Kingdom

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Références

Int J Technol Assess Health Care. 2020 Apr;36(2):173-178
pubmed: 32312340
J Health Organ Manag. 2012;26(3):293-316
pubmed: 22852453
Med Care. 1994 Nov;32(11):1069-85
pubmed: 7967849
Pharmacoecon Open. 2019 Sep;3(3):403-410
pubmed: 30617953
Int J Health Policy Manag. 2021 Mar 01;10(3):158-161
pubmed: 32610783
Value Health. 2020 Sep;23(9):1157-1162
pubmed: 32940233
J Comp Eff Res. 2019 Apr;8(5):275-278
pubmed: 30892064
Aust Health Rev. 2017 Mar;41(1):68-74
pubmed: 27050156
Health Policy. 2016 Jun;120(6):612-20
pubmed: 27086557
Int J Technol Assess Health Care. 2019;35(4):340-345
pubmed: 31292013
Int J Technol Assess Health Care. 2021 Apr 12;37(1):e54
pubmed: 33843518
Value Health. 2019 Jan;22(1):13-20
pubmed: 30661627
Int J Equity Health. 2012 Jun 07;11:30
pubmed: 22676204
Int J Technol Assess Health Care. 2021 Feb 09;37:e37
pubmed: 33557969
Appl Health Econ Health Policy. 2018 Dec;16(6):819-836
pubmed: 30073485
Patient. 2021 Jul;14(4):435-445
pubmed: 33462773
Value Health. 2020 Jan;23(1):32-38
pubmed: 31952671
Glob Heart. 2012 Mar;7(1):13-34
pubmed: 25691165
Int J Technol Assess Health Care. 2018 Jan;34(3):241-247
pubmed: 29888696
Int J Technol Assess Health Care. 2020 Aug 04;:1-8
pubmed: 32746954
Int J Technol Assess Health Care. 2019;35(6):467-473
pubmed: 31190670
Int J Health Policy Manag. 2020 Sep 01;9(9):390-402
pubmed: 32610740
Soc Sci Med. 2011 Jul;73(1):135-44
pubmed: 21664018
Int J Health Policy Manag. 2018 Jul 04;7(11):973-976
pubmed: 30624870
BMC Health Serv Res. 2009 Mar 05;9:43
pubmed: 19265518
Value Health. 2020 Apr;23(4):409-415
pubmed: 32327155
Health Policy. 2019 Feb;123(2):191-202
pubmed: 30554792
J Comp Eff Res. 2012 Mar;1(2):137-46
pubmed: 24237374
Soc Sci Med. 2003 Jul;57(2):239-51
pubmed: 12765705
Res Involv Engagem. 2021 Jan 05;7(1):1
pubmed: 33402216
J R Soc Interface. 2018 Apr;15(141):
pubmed: 29669894
Int J Technol Assess Health Care. 2018 Jan;34(3):248-253
pubmed: 29888698
Palliat Med. 2017 Feb;31(2):181-192
pubmed: 27280411
Value Health. 2017 Sep;20(8):1121-1130
pubmed: 28964444
Int J Technol Assess Health Care. 2020;36(1):29-33
pubmed: 31944173
Int J Technol Assess Health Care. 2020 Dec 23;37:e11
pubmed: 33353568
Milbank Q. 2014 Jun;92(2):319-50
pubmed: 24890250
Int J Technol Assess Health Care. 2019;35(4):253-256
pubmed: 31250778
Maturitas. 2009 May 20;63(1):4-6
pubmed: 19372017
Hastings Cent Rep. 2012 Mar-Apr;42(2):17-20
pubmed: 22733325
Soc Sci Med. 2005 Dec;61(11):2355-62
pubmed: 15950347
J Health Polit Policy Law. 2019 Aug 1;44(4):631-663
pubmed: 31305914
Int J Technol Assess Health Care. 2016 Jan;32(4):256-264
pubmed: 27670693

Auteurs

Wija Oortwijn (W)

Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: w.oortwijn@radboudumc.nl.

Don Husereau (D)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.

Julia Abelson (J)

Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, Canada.

Edwine Barasa (E)

Health Economics Research Unit (HERU), KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Diana Dana Bayani (DD)

Health Intervention and Policy Evaluation Research (HIPER), Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Vania Canuto Santos (V)

Department of Management and Incorporation of Health Technology, Executive Secretariat of National Committee Health Technology Incorporation (CONITEC), Ministry of Health, Brasilia, Brazil.

Anthony Culyer (A)

Centre for Health Economics, University of York, York, United Kingdom.

Karen Facey (K)

Evidence Based Health Policy Consultant, Drymen, Scotland.

David Grainger (D)

Biointelect, Sydney, Australia.

Katharina Kieslich (K)

Department of Political Science, Centre for the Study of Contemporary Solidarity, University of Vienna, Vienna, Austria.

Daniel Ollendorf (D)

Center for the Evaluation of Value and Risk in Health (CEVR), Tufts University Medical Centre, Boston, MA, USA.

Andrés Pichon-Riviere (A)

Institute for Clinical Effectiveness and Health Policy (IECS), University of Buenos Aires, Buenos Aires, Argentina.

Lars Sandman (L)

National Centre for Priorities in Health, Linköping University, Linköping, Sweden.

Valentina Strammiello (V)

European Patients' Forum, Brussels, Belgium.

Yot Teerawattananon (Y)

Health Intervention and Technology Assessment Programme (HITAP), Ministry of Health, Bangkok, Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH